Cardio Diagnostics Holdings Uses AI, Genetics and Epigenetics to Improve Cardiovascular Risk Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) is harnessing artificial intelligence, genetics, and epigenetics to advance cardiovascular risk detection, as highlighted in a recent article. The piece emphasizes the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease, a leading cause of death globally.

Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health, and biopharma solutions designed to leverage AI, epigenetics, and genetics to improve cardiovascular disease prevention, detection, and management. The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing.

Cardio Diagnostics currently offers two clinical solutions, Epi+Gen CHD and PrecisionCHD, as well as a population health and biopharma offering, HeartRisk and CardioInnovate360, respectively. Collectively, these solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care, from early detection and prevention to therapeutic development and population-level risk management.

The company’s AI-powered precision cardiovascular medicine approach makes prevention, detection, and management more accessible, personalized, and precise. By leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease, Cardio Diagnostics aims to become a leading medical technology company for improving prevention, detection, and treatment of cardiovascular disease.

For more information, visit the company’s newsroom at https://ibn.fm/CDIO or view the full article at https://ibn.fm/Nfps9.